CITY-FXI | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

2,211 results for “CITY-FXI”

Trials

View all 1050 →

A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, and Adults With a History of Provoked Venous Thromboembolism

182 participants · First posted Feb 24, 2026

Active, not recruiting

Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

40 participants · First posted May 6, 2023

Not yet recruiting

CITY

27 participants · First posted Sep 26, 2025

Drugs

View all 196 →

FXI-GalNAc-siRNA

BAFF-R targeted monoclonal antibody (City of Hope)

BAY-2976217

Organizations

View all 152 →

MATSUMOTO CITY

Japan

YOKOHAMA CITY

Japan

NAGOYA CITY UNIVERSITY

Japan

News

View all 813 →

Clinical-Stage RNAi Developer City Therapeutics Files for Nasdaq IPO

Waters Receives FDA 510(k) Clearance for BD BACTEC FXI Culture System, Accelerating Bloodstream Infection Diagnostics

CRISPR Therapeutics and Sirius Therapeutics Dose First Patient in Phase 2 Trial of SRSD107 for Venous Thromboembolism Prevention

Page 1 of 222